In this study, we investigated the clinical characteristics and laboratory test profiles of 95 pediatric patients with R/R B-ALL or B-NHL who received CD19- and CD22- targeted CAR-T cell therapy. This evidence concerns the gene CD22 and non-Hodgkin lymphoma.